Primary Perianal Malignant Melanoma in a Dog - Combination Therapy

Authors

  • Ygor Amaral Rossi Resident in Veterinary Surgery, Veterinary Hospital Veterinário Universidade de Franca https://orcid.org/0000-0002-4067-2771
  • Leticia Ribeiro Self-employed veterinarian in Santa Clara Clinic, Garça, São Paulo
  • Regina Mendes Medeiros Self-employed veterinarian in Santa Clara Clinic, Garça, São Paulo
  • Enrico Pierluigi Spugnini Biopulse srl, Naples, Italy https://orcid.org/0000-0003-3487-485X
  • Carlos Eduardo Fonseca-Alves Department of Veterinary Surgery and Animal Reproduction, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil and Institute of Health Sciences, Universidade Paulista – UNIP, Bauru, São Paulo, Brazil. https://orcid.org/0000-0002-6702-6139
  • Denner Santos Dos Anjos Eletro-Onkovet Service https://orcid.org/0000-0003-1804-475X

DOI:

https://doi.org/10.22456/1679-9216.117948

Abstract

Background: Melanocytic neoplasm can arise from melanocytes in any location of the body. Malignant melanoma (MM) has a poor prognosis in dogs and presence of lymphvascular invasion, distant metastasis, or mitotic activity present prognostic value. Primary melanoma affecting the gastrointestinal tract has been rarely reported in veterinary literature, thus the prognosis affecting gastrointestinal tract is unknown. Electrochemotherapy (ECT) is an effective local treatment which combines chemotherapeutic drugs mainly bleomycin or cisplatin followed by the delivery of permeabilizing electrical pulses However, other hydrophilic drugs seem to present an increase cytotoxic effect such as carboplatin.

Case: A 9-year-old mixed-breed neutered dog was referred to a private clinic with a mass in the perianal region diagnosed as perianal melanoma. No metastasis was observed on abdominal ultrasound nor chest x-ray (3 views). Clinical signs noted were tenesmus, hemorrhagic discharge, weight loss and hyporexia. Considering the tumor volume (16.0 x 10.0 cm), a neoadjuvant ECT session was proposed. The authors opted for carboplatin (300 mg/m², intravenously), administered over 20 min and cisplatin intratumorally (1 mg/cm³, equivalent to 1 mL/1cm³; total volume 20 mL) administered in the upper parts of the mass that could be reached while avoiding drug leakage. After administration, sequences of eight biphasic pulses, (100 microseconds), with a voltage ranging from 650-1,000V/cm (pulse generator Onkodisruptor®) using a hexagonal/single pair and plate electrode were delivered. At day 30th, a partial response was observed accordingly to RECIST system, with tumor size of 5.0 x 5.0 cm (65.4 cm³). A second ECT session was performed with the same previous protocol, but with a decreased dosage of carboplatin (240 mg/m² consistent with 20% reduction) due to adverse effects in the first session, resulting in stable disease at day 60th (30 days after second ECT). Then, we proposed a surgical excision of the mass including partial resection of ventral rectum with intraoperative ECT. Afterwards, it was observed fecal incontinence that did not resolved after time but did not significant cause a morbidity in the patient. Patient achieved a disease-free interval (DFI) of 700 days and survival time of 730 days. Unfortunately, patient died due to distant metastasis.

Discussion: Surgery is still the cornerstone treatment for MM in dogs, regardless anatomic site. However, in perianal region, wide or radical local surgical excision is a challenge due to anatomic region which precluded most of the time to achieve complete margins. In this report, the origin of the tumors was not defined since no normal tissue was found surrounding tumors cells probably due to tumor invasion and destruction of surrounding tissue. Thus, based on the previous literature, this tumor could have been arisen from rectum wall or anal sac. The longer DFI and survival time from this patient is superior from the most veterinary cases in literature which combined different types of treatment such as surgery, chemotherapy, immunotherapy, palliative care or ECT. Neoadjuvant ECT leaded to a reliable approach for partial remission in order to perform a better surgical approach in this case report. To conclude, ECT may be an option for partial remission and local control in regions which anatomic limitation is a challenge for wide excision.

Keywords: bleomycin, carboplatin, cisplatin, electroporation, melanocytic tumor.

Downloads

Download data is not yet available.

References

Clarke L.L. & Rissi D.R. 2018. Malignant rectal melanoma in 2 dogs. Canadian Veterinary Journal. 59: 152-154.

Dos Anjos D.S., Bueno C., Magalhaes L.F., Magalhaes G.M., Mattos Jr. E., Pinto M.M.R., De Nardi A.B., Brunner C.H.M., Leis-Filho A.F., Calazans S.G. & Fonseca-Alves C.E. 2019. Electrochemotherapy induces tumor regression and decreases the proliferative index in canine cutaneous squamous cell carcinoma. Scientific Reports. 9: 15819.

Goldschmidt M.H. & Shofer F.S. 1992. Skin tumors. In: Skin Tumors of the Dog and Cat. Oxford: Butterworth Heinemann, pp.142-151.

Kim D.Y., Mauldin G.E., Hosgood G. & Cho D.Y. 2005. Perianal malignant melanoma in a dog. Journal of Veterinary Internal Medicine. 19(4): 610-612.

Kubota Y., Tomita Y., Tsukigi M., Kurachi H., Motoyama T. & Mir L.M. 2005. A case of perineal malignant melanoma successfully treated with electrochemotherapy. Melanoma Research. 15(2): 133-134.

Smedley R.C., Spangler W.L., Esplin D.G., Kitchell B.E., Bergman P.J., Ho H.Y., Bergin I.L. & Kiupel M. 2011. Prognostic Markers for Canine Melanocytic Neoplasms: A Comparative Review of the Literature and Goals for Future Investigation. Veterinary Pathology. 48(1): 54-72.

Spugnini E.P., Dragonetti E., Vincenzi B., Onori., Citro G. & Baldi A. 2006. Pulse-mediated chemotherapy enhanceslocal control and survival in a spontaneous canine model of primarymucosal melanoma. Melanoma Research. 16: 23-27.

Spugnini E.P., Filipponi M., Romani L., Dotsinsky I., Mudrov N., Baroni A., Ruocco E., Laieta M.T., Montesarchio V., Cassandro R., Citro G. & Baldi A. 2007. Local control and distant metastasis after electrochemotherapy of a canine anal melanoma. In vivo. 21: 897-900.

Spugnini E.P. & Baldi A. 2019. Electrochemotherapy in Veterinary Oncology: State-of-the-Art and Perspectives. Veterinary Clinics of North American Small Animal Practice. 49: 967-979.

Souza C., Villarino N.F., Farnsworth K. & Black M.E. 2017. Enhanced cytotoxicity of bleomycin, cisplatin, and carboplatin on equine sarcoid cells following electroporation-mediated delivery in vitro. Journal of Veterinary Pharmacology and Therapeutics. 40(1): 97-100.

Vinayak A., Frank C.B., Gardiner D.W., Thieman-Mankin K.M. & Worley D.R. 2017. Malignant anal sac melanoma in dogs: eleven cases (2000 to 2015). Journal of Small Animal Practice. 58: 231-237.

Published

2022-02-02

How to Cite

Rossi, Y. A., Ribeiro, L., Medeiros, R. M., Spugnini, E. P., Fonseca-Alves, C. E., & Dos Anjos, D. S. (2022). Primary Perianal Malignant Melanoma in a Dog - Combination Therapy. Acta Scientiae Veterinariae, 50. https://doi.org/10.22456/1679-9216.117948

Most read articles by the same author(s)